These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 39174943)
1. Situational prevention in migraine: are we doing the right thing? Pellesi L; Martelletti P J Headache Pain; 2024 Aug; 25(1):137. PubMed ID: 39174943 [TBL] [Abstract][Full Text] [Related]
2. The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. van Hoogstraten WS; MaassenVanDenBrink A J Headache Pain; 2019 May; 20(1):54. PubMed ID: 31096904 [TBL] [Abstract][Full Text] [Related]
3. Evaluating rimegepant for the treatment of migraine. de Vries T; Al-Hassany L; MaassenVanDenBrink A Expert Opin Pharmacother; 2021 Jun; 22(8):973-979. PubMed ID: 33648385 [No Abstract] [Full Text] [Related]
4. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Moreno-Ajona D; Pérez-Rodríguez A; Goadsby PJ Curr Opin Neurol; 2020 Jun; 33(3):309-315. PubMed ID: 32251023 [TBL] [Abstract][Full Text] [Related]
5. Update of Gepants in the Treatment of Chronic Migraine. Cho S; Kim BK Curr Pain Headache Rep; 2023 Oct; 27(10):561-569. PubMed ID: 37656319 [TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Croop R; Berman G; Kudrow D; Mullin K; Thiry A; Lovegren M; L'Italien G; Lipton RB Cephalalgia; 2024 Apr; 44(4):3331024241232944. PubMed ID: 38659334 [TBL] [Abstract][Full Text] [Related]
7. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325 [TBL] [Abstract][Full Text] [Related]
13. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Chiang CC; Schwedt TJ Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505 [TBL] [Abstract][Full Text] [Related]
14. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Tepper SJ Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830 [TBL] [Abstract][Full Text] [Related]
15. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. Lipton RB; Croop R; Stock EG; Stock DA; Morris BA; Frost M; Dubowchik GM; Conway CM; Coric V; Goadsby PJ N Engl J Med; 2019 Jul; 381(2):142-149. PubMed ID: 31291516 [TBL] [Abstract][Full Text] [Related]
16. Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review. DeFalco AP; Lazim R; Cope NE Ann Pharmacother; 2021 May; 55(5):650-657. PubMed ID: 32909437 [TBL] [Abstract][Full Text] [Related]
17. A systematic review with expert opinion on the role of gepants for the preventive and abortive treatment of migraine. Argyriou AA; Mantovani E; Mitsikostas DD; Vikelis M; Tamburin S Expert Rev Neurother; 2022 Jun; 22(6):469-488. PubMed ID: 35707907 [TBL] [Abstract][Full Text] [Related]
18. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640 [TBL] [Abstract][Full Text] [Related]
19. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis. Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463 [TBL] [Abstract][Full Text] [Related]
20. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review. Dos Santos JBR; da Silva MRR Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]